Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
Pfizers BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial…
Pfizers BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial…
Tango Networks Recognized by Frost & Sullivan for Enabling Collaboration Among Distributed Teams and improved Employee-customer Interactions with Its Global Business Mobility Solution
Tango Extend provides organizations with a cost-effective, non-disruptive, reliable, and compliant mobile…
Tango Networks Recognized by Frost & Sullivan for Enabling Collaboration Among Distributed Teams and improved Employee-customer Interactions with Its Global Business Mobility Solution
Tango Extend provides organizations with a cost-effective, non-disruptive, reliable, and compliant mobile…
Duos Technologies Group Reports Improved Third Quarter 2024 Results
JACKSONVILLE, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc.…
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Improved operating performance by reducing net loss by $52.5 million; reported net…